Open Access

MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients

  • Authors:
    • Huina Lu
    • Yi Ding
    • Yan Dong
    • Xiu Luo
    • Xiuqin Wang
    • Bing Xiu
    • Aibin Liang
    • Wenjun Zhang
  • View Affiliations

  • Published online on: August 5, 2022     https://doi.org/10.3892/ol.2022.13450
  • Article Number: 330
  • Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to explore the correlation of microRNA (miR)‑181b‑5p expression with treatment response and long‑term prognosis in acute myeloid leukemia (AML) patients. miR‑181b‑5p was detected in the bone marrow of 84 AML patients before therapy. After induction therapy, the patients exhibiting complete remission (CR) were recorded. Next, event‑free survival (EFS) and overall survival (OS) were calculated. miR‑181b‑5p had excellent potential to discriminate AML patients from healthy donors [area under the curve (AUC): 0.922, 95% confidence interval (CI): 0.873‑0.971)]. In addition, miR‑181b‑5p expression was decreased in AML patients with the FLT3‑ITD mutation (P=0.032) or WT1 mutation (P=0.017) when compared to AML patients without these genetic mutations. Meanwhile, miR‑181b‑5p expression was negatively correlated with the National Comprehensive Cancer Network (NCCN) risk classification of AML (P=0.036). Furthermore, miR‑181b‑5p expression was elevated in CR AML patients compared to non‑CR AML patients (P=0.030). Moreover, higher miR‑181b‑5p expression was associated with favorable accumulating EFS (P=0.001) and OS (P=0.024). In addition, higher miR‑181b‑5p expression was independently associated with better EFS (hazard ratio: 0.698, P=0.012). In conclusion, miR‑181b‑5p insufficiency is associated with induction therapy response failure, unfavorable accumulating EFS and OS in AML patients.

Related Articles

Journal Cover

October-2022
Volume 24 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lu H, Ding Y, Dong Y, Luo X, Wang X, Xiu B, Liang A and Zhang W: MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients. Oncol Lett 24: 330, 2022
APA
Lu, H., Ding, Y., Dong, Y., Luo, X., Wang, X., Xiu, B. ... Zhang, W. (2022). MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients. Oncology Letters, 24, 330. https://doi.org/10.3892/ol.2022.13450
MLA
Lu, H., Ding, Y., Dong, Y., Luo, X., Wang, X., Xiu, B., Liang, A., Zhang, W."MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients". Oncology Letters 24.4 (2022): 330.
Chicago
Lu, H., Ding, Y., Dong, Y., Luo, X., Wang, X., Xiu, B., Liang, A., Zhang, W."MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients". Oncology Letters 24, no. 4 (2022): 330. https://doi.org/10.3892/ol.2022.13450